SIGA TECHNOLOGIES INC(SIGA)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
SIGA TECHNOLOGIES INC (SIGA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SIGA at 14.9/100 on a 32-signal composite quality model, placing it at rank #2,861 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.3) and revenue scale (9.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 28.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SIGA TECHNOLOGIES INC reports quarterly revenue of $41.0M, net income of $12.5M. Top institutional holders of SIGA by reported 13-F value include BlackRock, DIMENSIONAL FUND ADVISORS, AltraVue Capital, based on the most recent SEC filings. SIGA trades on the Nasdaq exchange and files with the SEC under CIK 1010086. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SIGA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SIGA TECHNOLOGIES INC directly from SEC EDGAR.
AI Quality Score
14.9/100
AI Rank
#2,861
Revenue
$41.0M
Net Income
$12.5M
SIGA key financials by period
SIGA TECHNOLOGIES INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$94.6M
$23.3M
25.1%
FY 2024
10-K
$138.7M
$59.2M
50.4%
FY 2023
10-K
$139.9M
$68.1M
59.8%
FY 2022
10-K
$110.8M
$33.9M
38.6%
FY 2021
10-K
$133.7M
$69.5M
66.6%
FY 2020
10-K
$125.0M
$56.3M
67.6%
Institutions holding SIGA
Institutional investors reporting a position in SIGA TECHNOLOGIES INC on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-06 — Q2 FY2026 (six months ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
SIGA revenues fell 46% YoY to $47.2M in H1 2026 as U.S. Government TPOXX orders declined sharply, though international sales of $13M and R&D revenue growth partially offset the drop.
Biggest Revenue Drivers
Research and development$5.8M+81% YoY
Increase in billable activities under the 19C BARDA Contract
Biggest Revenue Drivers
Total revenue: $47.2M-46% YoY
Research and development$5.8M+81% YoY
Increase in billable activities under the 19C BARDA Contract
Largest Expense Items
Cost of sales and supportive services$20.5M-20% YoY
Primarily associated with manufacture and delivery of IV TPOXX to U.S. Government and oral TPOXX to international countries
Research and development$8.3M+5% YoY
Increase in direct vendor costs under 19C BARDA Contract and EMA referral procedure costs for mpox, offset by lower self-funded R&D
Selling, general and administrative$9.8M-12% YoY
Lower corporate expenses in consulting, professional services, and international business development, partially offset by higher compensation
Margins: Gross margin on product sales improved as IV TPOXX revenue mix shifted, with lower cost of sales as a percentage of revenue. Operating income declined 80% YoY to $8.6M as the significant revenue decline outpaced SG&A expense reductions.
Watch Items from the Filing
U.S. Government represents majority of revenue via 19C BARDA Contract; H1 2026 U.S. product revenue declined 81% YoY to $28.0M as contract deliveries slowed.
19C BARDA Contract contemplates ~$630M in total payments, of which ~$545.2M exercised options remain undelivered; IV TPOXX expected gross margin below 40%.
EMA/MHRA removed mpox indication from Tecovirimat-SIGA (May 2026) following failed clinical trials (PALM007, STOMP); label now restricted to smallpox, cowpox, vaccinia complications.
New MENA license agreement with Hikma (March 2026) and international sales of $13M in H1 2026 represent emerging diversification beyond U.S. Government procurement.
Cash declined $37.4M to $117.6M in H1 2026 due to $43.3M special dividend paid in April 2026 and reduced operating cash generation ($6.5M vs $70.1M YoY).
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
